fda changes to tirzepatide Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management F.D.A. Approves New Obesity Drug

Direct healthcare-professional communication (DHPC) Available from: 86

This is the fastest way to get your prescription to the new pharmacy

Throughout this article, we will explore how tirzepatide works, what the research says, and whether it might be the right choice for you

no clear plateau) Zepbound: ~20% to 22.5% (long-term studies) Glycemic Control (T2D): Retatrutide: HbA1c reduction up to ~2.0% (Phase III) Zepbound: Strong, well-established HbA1c reductions (~2.0% to 2.4%) across Phase III trials Durability of Effect: Retatrutide: Sustained weight loss with continued decline over time Zepbound: Durable, but tends to plateau earlier Safety & Tolerability: Retatrutide: Higher rates of GI side effects

Probiotics and Prebiotics If GLP-1 had a hype team, your gut would be running the show

Dietary and lifestyle modifications are typically the first-line approach: Eat smaller, more frequent meals rather than large portions Avoid lying down for at least two to three hours after eating Elevate the head of the bed by 1520 cm if nocturnal symptoms are present Reduce or avoid known reflux triggers such as fatty or spicy foods, caffeine, alcohol, and carbonated drinks Maintain a healthy weight, as excess abdominal weight increases intra-abdominal pressure Pharmacological management may also be appropriate in some cases